Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
- Published In:
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(14), 2292-8 (2008)
- Authors:
- Sosman, Jeffrey A, Carrillo, Carole, Urba, Walter J, Flaherty, Lawrence, Atkins, Michael B, Clark, Joseph I, Dutcher, Janet, Margolin, Kim A, Mier, James, Gollob, Jarod, Kirkwood, John M, Panka, David J, Crosby, Nancy A, O'Boyle, Kevin, LaFleur, Bonnie, Ernstoff, Marc S
- Database ID:
- RPEP-01420
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01420APA
Sosman, Jeffrey A; Carrillo, Carole; Urba, Walter J; Flaherty, Lawrence; Atkins, Michael B; Clark, Joseph I; Dutcher, Janet; Margolin, Kim A; Mier, James; Gollob, Jarod; Kirkwood, John M; Panka, David J; Crosby, Nancy A; O'Boyle, Kevin; LaFleur, Bonnie; Ernstoff, Marc S. (2008). Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(14), 2292-8. https://doi.org/10.1200/JCO.2007.13.3165
MLA
Sosman, Jeffrey A, et al. "Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008. https://doi.org/10.1200/JCO.2007.13.3165
RethinkPeptides
RethinkPeptides Research Database. "Three phase II cytokine working group trials of gp100 (210M)..." RPEP-01420. Retrieved from https://rethinkpeptides.com/research/sosman-2008-three-phase-ii-cytokine
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.